Endocrine Abstracts

Introduction: The current guidelines state that the goals of growth hormone (GH) therapy should be an appropriate clinical response and avoidance of side effects. The target level for IGF1 is commonly the upper half of the reference range, although no published studies offer specific guidance in this regard. Therefore, the aim of the present study is to investigate associations between IGF1 levels within the reference range and several efficacy and safety measures of GH treatm...

Objective: Epidemiological evidence for a link between serum IGF1 concentration and cardiovascular disease in the general population and in patients with GH deficiency or hypersecretion has been demonstrated. However, the underlying mechanisms remain unresolved. We investigated associations between IGF1 levels within the reference range and different measures of cardiovascular function and risk factors in substituted GH deficient adults within a randomized clinical trial.<...

Objective: Growth hormone treatment (GHT) is a widely accepted treatment in growth hormone deficient (GHD) adults with nonfunctioning pituitary adenoma (NFPAs). However, concerns remain about the safety of GHT, because of its potentially stimulating effect on tumour (re)growth. The aim of this study was to evaluate tumour progression in NFPA patients using GHT.Patients and methods: From the Dutch National Registry of growth hormone treatment in adults, a...